Get started
BIOCRYST PHARMACTLBIOCRYST PHARMACTLBIOCRYST PHARMACTL

BIOCRYST PHARMACTL

No trades
See on Supercharts
Overview
Financials News Ideas Forecast

BO1 chart

Upcoming earnings

Next report date
Report period
Q1 2024
EPS estimate
−0.19CHF
Revenue estimate
‪77.24 M‬CHF

Key stats

Market capitalization
‪811.34 M‬CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.992CHF
Net income (FY)
‪−190.73 M‬CHF
Revenue (FY)
‪279.03 M‬CHF
Shares float
‪198.73 M‬
Beta (1Y)
0.81

About BioCryst Pharmaceuticals, Inc.

Sector
Health Technology
Industry
Biotechnology
CEO
Jon P. Stonehouse
Website
biocryst.com
Headquarters
Durham
Employees (FY)
536
Founded
1986
FIGI
BBG00LVDC0P9
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of BO1 is 12.290 CHF — it has decreased by 10.75% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange BIOCRYST PHARMACTL stocks are traded under the ticker BO1.
BIOCRYST PHARMACTL is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
BO1 stock is 12.05% volatile and has beta coefficient of 0.81. Check out the list of the most volatile stocks — is BIOCRYST PHARMACTL there?
BO1 earnings for the last quarter are −0.17 CHF per share, whereas the estimation was −0.22 CHF resulting in a 22.45% surprise. The estimated earnings for the next quarter are −0.21 CHF per share. See more details about BIOCRYST PHARMACTL earnings.
BIOCRYST PHARMACTL revenue for the last quarter amounts to ‪79.41 M‬ CHF despite the estimated figure of ‪78.79 M‬ CHF. In the next quarter revenue is expected to reach ‪75.75 M‬ CHF.
Yes, you can track BIOCRYST PHARMACTL financials in yearly and quarterly reports right on TradingView.
BO1 stock hasn't changed in a week, the last month showed zero change in price, over the last year there was no change in BIOCRYST PHARMACTL price.
BO1 net income for the last quarter is ‪−51.97 M‬ CHF, while the quarter before that showed ‪−33.09 M‬ CHF of net income which accounts for −57.05% change. Track more BIOCRYST PHARMACTL financial stats to get the full picture.
Today BIOCRYST PHARMACTL has the market capitalization of ‪811.34 M‬, it has increased by 8.05% over the last week.
No, BO1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BO1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOCRYST PHARMACTL stock right from TradingView charts — choose your broker and connect to your account.
BO1 reached its all-time high on Aug 30, 2021 with the price of 14.683 CHF, and its all-time low was 10.848 CHF and was reached on Nov 5, 2021.
See other stocks reaching their highest and lowest prices.
As of May 1, 2024, the company has 536.00 employees. See our rating of the largest employees — is BIOCRYST PHARMACTL on this list?
We've gathered analysts' opinions on BIOCRYST PHARMACTL future price: according to them, BO1 price has a max estimate of 26.93 CHF and a min estimate of 5.39 CHF. Read a more detailed BIOCRYST PHARMACTL forecast: see what analysts think of BIOCRYST PHARMACTL and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOCRYST PHARMACTL EBITDA is ‪−85.92 M‬ CHF, and current EBITDA margin is −30.79%. See more stats in BIOCRYST PHARMACTL financial statements.